Amgen’s Horizon Therapeutics Acquisition Receives FTC Approval with Safeguards to Protect Competition
Republished with full copyright permissions from The San Francisco Press. Amgen’s $28 billion acquisition of Horizon Therapeutics has been given the green light by the Federal Trade Commission (FTC) after a settlement was reached. The agreement includes measures aimed at preserving competition in two rare diseases currently monopolized by Horizon’s drugs. The settlement, announced on Friday, resolves the FTC’s lawsuit which sought to block the acquisition. In addition, six states that had also sued to halt the M&A deal—California, Illinois, Minnesota, New York, Washington, and Wisconsin—will now dismiss their suits. When Amgen initially announced the acquisition agreement with Dublin-based Horizon, … Continue reading Amgen’s Horizon Therapeutics Acquisition Receives FTC Approval with Safeguards to Protect Competition

